Indevus Pharmaceuticals, Inc. (IDEV)'s Valstar Reintroduced into Bladder Cancer Market  
3/3/2009 8:14:05 AM

Mar 02, 2009 (Datamonitor via COMTEX) -- Having previously been withdrawn due to purity concerns, Indevus Pharmaceuticals' Valstar has received FDA approval for reintroduction into the bladder cancer market. The drug should be able to reclaim its original market share, although this will require an effective marketing strategy.